On March 20, 2025, Monogram Technologies Inc. (NASDAQ: MGRM), an AI-driven robotics company, announced its new partnership with Urvin, a private platform designed exclusively for its shareholders.
This innovative initiative aims to enhance engagement among Monogram's shareholders, providing a dedicated space for communication and important company updates. Urvin only allows verified, actively registered Monogram shareholders to participate, ensuring that discussions remain relevant to those invested in the company's future.
As part of its strategy to strengthen shareholder relations, Monogram is keen on offering a more streamlined communication tool that can facilitate meaningful conversations among investors. The platform is set to help the company reach its shareholder audience more effectively compared to traditional outreach methods, which can often prove laborious and time-consuming.
To participate in the Urvin platform, shareholders need to create an account using the email address filed with the company’s transfer agent. This will allow them to access their Verified Shareholder Communities, a commitment by Monogram to foster stronger connections with its investors.
In addition to the benefits of Urvin, Monogram Technologies remains dedicated to innovation in health through its mBôs™ precision robotic surgical system, which autonomously executes paths for accurate insertion of FDA-cleared mPress press-fit implants. As the company continues to develop its solutions, Monogram is positioning itself at the forefront of orthopedic robotics, aiming for better-fitting and bone-sparing knee replacements.
Monogram Technologies Inc. believes that active shareholder engagement is crucial, especially during pivotal corporate events. The company is focused on ensuring its community of investors is well-informed about the developments taking place within the organization, which enhances transparency and trust.
Through Urvin, the company hopes to build a resourceful and interactive space for its shareholders, significantly improving the quality of engagement that investors can expect.
Meanwhile, another significant milestone in the healthcare sector took place on the same day. Johnson & Johnson (NYSE: JNJ) received FDA approval for TREMFYA® (guselkumab), marking its availability for treatment of adults with moderately to severely active Crohn's disease.
TREMFYA® is a notable product as it is the first and only IL-23 inhibitor that offers both subcutaneous and intravenous induction options. This approval is critical, considering that Crohn's disease is a chronic inflammatory condition impacting nearly three million Americans. It represents a significant advancement in the treatment landscape for patients suffering from this debilitating illness.
Supported by results from multiple Phase 3 trials, TREMFYA® demonstrated superior efficacy compared to STELARA® in achieving endoscopic remission. The GRAVITI study confirmed that the 400 mg subcutaneous induction of TREMFYA® resulted in a clinical remission of 56% versus 22% for placebo (p<0.001), showcasing its effectiveness in real-world settings.</p>
The flexibility of treatment methods available with TREMFYA® aims to optimize patient care and underscores J&J's commitment to providing comprehensive therapeutic options for those affected by Crohn's disease. Doctors can now offer patients a choice between subcutaneous injections or intravenous infusions, responding to their individual treatment preferences.
Chris Gasink, MD, Vice President, Medical Affairs at J&J, stated, "TREMFYA is the first and only IL-23 inhibitor that offers a fully subcutaneous treatment option for moderately to severely active Crohn's disease. With the approval of TREMFYA, it is now possible to achieve meaningful improvements in clinical and endoscopic outcomes with the flexibility of self-administration from the start."
This milestone builds upon prior approvals for TREMFYA® in the U.S., including treatments for ulcerative colitis, plaque psoriasis, and psoriatic arthritis. These sequential approvals highlight Johnson & Johnson's unwavering legacy of innovation in addressing chronic immune-mediated conditions.
In summary, March 20, 2025, serves as a pivotal moment for both Monogram Technologies and Johnson & Johnson. As Monogram enhances shareholder engagement through Urvin, J&J expands treatment accessibility for Crohn's disease with the advent of TREMFYA®. Both companies exemplify commitment to improving health outcomes and maintaining robust stakeholder relations.
